$XBI $87.77 | -2.92%
Covid Updates
$PFE 0,0% & -2.3% BNTX Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age source
Pipeline Updates
$NKTR -19.6% Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) source
$PTCT -1.6% PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program source
$CHRS -3.4% Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States source
$GALT +10.1% Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis source
$EXEL +0.4% Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma source
$EWTX +2.4% Edgewise-Funded Natural History Trial Of Becker Muscular Dystrophy (BMD) Now Enrolling source
$ADGI -7.2% ADAGIO THERAPEUTICS PROVIDES UPDATE ON TIMING OF ADINTREVIMAB EUA REQUEST source
$SURF -3.0% Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer source
$CTIC -3.4% NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms source
$EVLO -1.6% Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs source
Business Updates
$TXMD -3.8% TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million source
$SLGL +9.9% Sol-Gel Technologies Announces the Commercial Availability of TWYNEO® source
$AGRX -13.1% AGILE THERAPEUTICS ANNOUNCES FIRST QUARTER 2022 PRESCRIPTION DATA FOR TWIRLA® source
Posted by JM
Comentários